Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	790299-79-5
Formula :	C₂₈H₃₀N₆OS
M.W :	498.64
SMILES Code :	O=C(NC1=CC=C(C(NC2=NC(C3=CC=CN=C3)=CS2)=C1)C)C4=CC=C(CN5CCN(CC5)C)C=C4
Synonyms :	AB1010; Masican; Masiviera
MDL No. :	MFCD09954132

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302
Precautionary Statements:	P280-P305+P351+P338

A549 cells	10 µM	2 days	inhibition of SARS-CoV-2 infection	PMC8809056
293T cells	10 µM		inhibition of 3CL protease activity	PMC8809056
CCRF-CEM cells	10 µM	72 hours	Evaluate the anti-proliferative effect of Masitinib in the T-ALL cell line CCRF-CEM, results showed that Masitinib was unable to inhibit cancer cell proliferation.	PMC10227015
HUVEC	0.3, 1, 3 µM	12 hours	To evaluate the inhibitory effect of Masitinib on HUVEC cell migration, results showed that Masitinib significantly inhibited VEGF-induced HUVEC cell migration.	PMC10657461
HCAEC	0.3, 1, 3 µM	12 hours	To evaluate the inhibitory effect of Masitinib on HCAEC cell migration, results showed that Masitinib significantly inhibited VEGF-induced HCAEC cell migration.	PMC10657461
NI-1 cells	0.1 – 0.2 µM	48 h	To evaluate the inhibitory effect of Masitinib on the proliferation of NI-1 cells, the results showed that Masitinib had a weak inhibitory effect on the proliferation of NI-1 cells.	PMC3401908
C2 cells	0.025 – 0.05 µM	48 h	To evaluate the inhibitory effect of Masitinib on the proliferation of C2 cells, the results showed that Masitinib had a good inhibitory effect on the proliferation of C2 cells.	PMC3401908
HMC-1.1 cells	0.005 – 0.01 µM	48 h	To evaluate the inhibitory effect of Masitinib on the proliferation of HMC-1.1 cells, the results showed that Masitinib had a good inhibitory effect on the proliferation of HMC-1.1 cells.	PMC3401908
HMC-1.2 cells	>2 µM	48 h	To evaluate the inhibitory effect of Masitinib on the proliferation of HMC-1.2 cells, the results showed that Masitinib had a weak inhibitory effect on the proliferation of HMC-1.2 cells.	PMC3401908

mice	K18-hACE2 transgenic mice	oral	25 mg/kg or 50 mg/kg	Once daily for 14 days	reduction of SARS-CoV-2 viral load, improvement in lung inflammation and survival rate	PMC8809056
Mice	NOD-SCID-IL2Rγc null (NSG) mouse model	Intraperitoneal injection	25 mg/kg	twice daily for 10 days	Evaluate the anti-leukemic effect of OR0642 in combination with dT in a T-ALL mouse model, results showed that the combination therapy significantly reduced leukemic burden and prolonged mouse survival.	PMC10227015
Mice	CAWS-induced KD murine model	Oral	10 μmol/kg	Single injection	To evaluate the regulatory effect of Masitinib on cardiovascular pathology in the KD murine model, results showed that Masitinib significantly reduced VEGF-induced endothelial cell migration and improved vascular and cardiac inflammatory damage.	PMC10657461
Mice	SOD1G93A mouse model	Oral gavage	5% Palmitic Acid	Continued for 20 weeks	Masitinib reduced the number of mast cells and the influx of mast cell precursors in the spinal cord of ALS mice by inhibiting c-Kit, and improved microvascular pathology.	PMC8361844

{[proInfo.proName]}

CAS No.: 790299-79-5

{[proInfo.proName]}

CAS No.: 790299-79-5

Alternative Products

Product Details of Masitinib

Safety of Masitinib

Related Pathways of Masitinib

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

NCT00831922	Rheumatoid Arthritis	Phase 2	Completed	-	-
NCT00831974	Mastocytosis	Phase 2	Completed	-	-
NCT01045577	Psoriasis	Phase 2	Completed	-	-
NCT01433497	Multiple Sclerosis, Secondary ... More >>Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Relapse Free Less <<	Phase 3	Active, not recruiting	March 2019	Spain ... More >> Hospital de la Santa Creu i Sant Pau Barcelona, Spain, 08041 Less <<
NCT01450488	Multiple Sclerosis	Phase 2	Completed	-	-
NCT00842270	Asthma	Phase 2	Completed	-	-
NCT00866138	Multiple Myeloma	Phase 2	Completed	-	France ... More >> Hopital Saint Louis Paris, France Less <<
NCT02605044	Metastatic Colorectal Cancer	Phase 3	Terminated(Sponsor decision ba... More >>sed on portfolio prioritization) Less <<	-	France ... More >> Hopital Europeen George Pomipidou, Hepato-Gastro-enterologie, 20 rue Leblanc Paris, France, 75 Singapore National Cancer Center, 11 Hospital Drive Singapore, Singapore, 169610 United Kingdom Hammersmith Hospital, Department of Cancer Medicine, Imperial College Healthcare Trust, Du Cane Road London, United Kingdom, W12 0HS Less <<
NCT00789633	Pancreatic Cancer	Phase 3	Completed	-	-
NCT02490488	Ovarian Cancer	Phase 2 Phase 3	Recruiting	December 2020	France ... More >> Institut Sainte Catherine Recruiting Avignon, France, 84000 Contact: Julien GRENIER, MD Less <<
NCT00812240	Gastrointestinal Stromal Tumor... More >>s Less <<	Phase 3	Terminated(Sponsor decision ba... More >>sed on portfolio prioritization) Less <<	-	-
NCT01266369	Mastocytosis	Phase 2	Completed	-	-
NCT01506336	Gastro Intestinal Stromal Tumo... More >>r Less <<	Phase 2	Completed	-	France ... More >> Institute Gustave Roussy (IGR) Villejuif, France, 94815 Less <<
NCT03127267	Amyotrophic Lateral Sclerosis	Phase 3	Not yet recruiting	May 2024	-
NCT02009423	Gastro-Intestinal Stromal Tumo... More >>ur Less <<	Phase 3	Terminated(Sponsor decision ba... More >>sed on portfolio prioritization) Less <<	-	-
NCT01449162	Asthma	Phase 3	Active, not recruiting	March 2019	Hungary ... More >> University of Debrecen Medical and Health Science Center Debrecen, Hungary, 4032 Less <<
NCT01872598	Alzheimer Disease	Phase 3	Active, not recruiting	October 2019	Spain ... More >> Hospital Universitario Ramón y Cajal Madrid, Spain, 28034 Less <<
NCT01694277	Gastrointestinal Stromal Tumor... More >>s Less <<	Phase 3	Recruiting	December 2022	France ... More >> Institut Bergonié Recruiting Bordeaux, France, 33000 Less <<
NCT00998751	Gastro-intestinal Stromal Tumo... More >>urs Less <<	Phase 2	Completed	-	France ... More >> Lecesne Villejuif, France Less <<
NCT01410695	Rheumatoid Arthritis (RA)	Phase 2 Phase 3	Terminated(Sponsor decision ba... More >>sed on portfolio prioritization) Less <<	-	Czechia ... More >> ARTMEDI UPD s.r.o Hostivice, Czechia, 25301 Less <<
NCT01470131	Multiple Myeloma	Phase 3	Terminated(Sponsor decision ba... More >>sed on portfolio prioritization) Less <<	-	United States, Illinois ... More >> Medical and Surgical Specialists Galesburg, Illinois, United States, 61401 United States, Maryland Center for Cancer and Blood Disorders Bethesda, Maryland, United States, 20817 United States, North Carolina Carolinas Medical Center Charlotte, North Carolina, United States, 28203 Southeastern Medical Oncology Center Goldsboro, North Carolina, United States, 27534 United States, Wisconsin Froedtert & Medical College of Wisconsin-CLCC Milwaukee, Wisconsin, United States, 53226 France CHU Estaing Clermont Ferrand, France Centre Hospitalier Sud Francilien Corbeil-Essonnes, France CH Le Mans Le Mans, France Hôpital Universitaire Dupuytren Limoges, France Hôpital Ambroise Paré Marseille, France Hôpital de l'Hôtel Dieu Nantes, France Hôpital Saint Louis Paris, France Centre Hospitalier Saint Jean Perpignan, France Less <<
NCT03766295	Locally Advanced or Metastatic... More >> Pancreatic Cancer Less <<	Phase 3	Recruiting	December 2020	France ... More >> Centre Hospitalier de Longjumeau Recruiting Longjumeau, France, 91160 Less <<
NCT00976118	Alzheimer's Disease	Phase 2	Completed	-	-
NCT00814073	Indolent Systemic Mastocytosis	Phase 3	Completed	-	United States, California ... More >> UC Davis Health System , Department of Dermatology Sacramento, California, United States, 95816 United States, Texas MD Anderson Cancer Centre Houston, Texas, United States, 77030 France CHU d'Amiens Amiens, France Hôpital Avicenne Bobigny, France CHU de Brest Brest, France CHU de Caen Caen, France CHU Clermont Ferrand Clermont Ferrand, France, 63000 Hôpital Claude Huriez Lille, France CHU Dupuytren Limoges, France Hôpital Ambroise Paré Marseille, France Hôpital Nord Marseille, France Hôpital Central Nancy, France CHU Hôtel Dieu Nantes, France Hôpital l'Archet II Nice, France Hôpital Necker Paris, France Hôpital Tenon Paris, France CHU Lyon Sud Pierre Bénite, France, 69495 Centre Hospitalier Lyon Sud Pierre-Bénite, France CHU Milétrie Poitiers, France CHU Hôpital Sud Rennes, France CHU de Saint-Etienne Saint-Etienne, France Hôpital Purpan Toulouse, France Hôpital Bretonneau Tours, France Hôpital des Hauts Clos Troyes, France Less <<
NCT03761225	Metastatic Castrate Resistant ... More >>Prostate Cancer Less <<	Phase 3	Recruiting	September 2020	France ... More >> Polyclinique d'oncologie de Gentilly Recruiting Nancy, France, 54100 Contact: Dominique Spaeth, MD Less <<
NCT02588677	Amyotrophic Lateral Sclerosis ... More >>(ALS) Less <<	Phase 2 Phase 3	Completed	-	Spain ... More >> Hospital Carlos III Madrid, Spain, 28029 Less <<
NCT03556956	Colorectal Cancer Metastatic	PHASE2\|PHASE3	COMPLETED	2025-12-20	University Hospital Olomouc, O... More >>lomouc, 779 00, Czechia\|Chu - Hopitaux de Rouen, Rouen, France\|Omsk Clinical oncology dispensary, Omsk, 644013, Russian Federation\|Hospital Madrid Norte San Chinarro, Madrid, Spain\|Hammersmith Hospital Imperial College Healthcare Nhs Trust, London, United Kingdom Less <<
NCT00913432	Rheumatoid Arthritis	Phase 2	Completed	-	-
NCT01280565	Metastatic Melanoma	Phase 3	Recruiting	December 2020	France ... More >> Hôpital Sainte Marguerite Recruiting Marseille, France, 13274 Contact: Jean-Jacques GROB, MD, PhD Less <<
NCT03771040	Asthma	Phase 3	Recruiting	December 2020	Hungary ... More >> University of Debrecen Medical and Health Science Center Recruiting Debrecen, Hungary, 4032 Less <<

Bio Calculators
Preparing Stock Solutions		1mg	5mg	10mg
Preparing Stock Solutions	1 mM 5 mM 10 mM	2.01mL 0.40mL 0.20mL	10.03mL 2.01mL 1.00mL	20.05mL 4.01mL 2.01mL
Dissolving Methods	Animal experiment Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn: in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Protocol 1 Protocol 2

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed